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Abstract: Growing evidence points to exosomes as key mediators of cell–cell communication, by
transferring their specific cargo (e.g., proteins, lipids, DNA and RNA molecules) from producing to
receiving cells. In cancer, the regulation of the exosome-mediated intercellular communication
may be reshaped, inducing relevant changes in gene expression of recipient cells in addition
to microenvironment alterations. Notably, exosomes may deliver signals able to induce the
transdifferentiation process known as Epithelial-to-Mesenchymal Transition (EMT). In this review,
we summarize recent findings on the role of exosomes in tumor progression and EMT, highlighting
current knowledge on exosome-mediated intercellular communication in tumor-niche establishment,
migration, invasion, and metastasis processes. This body of evidence suggests the relevance of
taking into account exosome-mediated signaling and its multifaceted aspects to develop innovative
anti-tumoral therapeutic approaches.
Keywords: tumor niche; Epithelial–Mesenchymal plasticity; cancer-derived exosomes; extracellular
vesicles; metastasis
1. Introduction
The lipid-bilayer extracellular vesicles (EVs) include at least three main classes of vesicles that
differ in dimension, biogenesis and biophysical properties: exosomes, microvesicles, and apoptotic
bodies. Here, we focused on exosomes, small vesicles with an average diameter from 30 to 200 nm that
originate inside the Multi Vesicular Bodies (MVBs) and are released by the parental cell after MVB
fusion with plasma membrane.
Although exosomes were first identified as garbage disposal [1,2], current knowledge highlights
the direct role of these vesicles in governing physiological and pathological conditions by transferring
information from producing to receiving cells. Exosomes, indeed, may signal in autocrine but, most
importantly, in paracrine and endocrine manner, being taken up by neighboring cells or carried to
distant sites. Thus, they assure the horizontal transfer of specific bioactive molecules (including
proteins, lipids, RNAs, and DNA [3]) from donor to recipient cells.
Exosomes are ordinarily released by different cell types [4]. They have been identified in various
body fluids (including semen, blood, urine, cerebrospinal fluid, and milk) and their role is strongly
associated with the cytotype of the producing cells. For example, exosomes participating in supporting
immune response [5] and, as vesicles secreted by cells of the nervous system, have been found to
coordinate myelin membrane biogenesis, neuronal development, transmission and regeneration [6–8].
Interestingly, several studies recently reviewed by Guay and Reguazzi [9], pointed to the involvement
of exosomes in a “new endocrinology”, being mediators of the crosstalk between metabolic organs.
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Despite the exosome role in homeostasis maintenance and physiology, the most recent intensive
investigation was focused on the involvement of these EVs in pathological processes. Particularly
in cancer, the regulation of the exosome-mediated intercellular communication may be reshaped.
Exosomes, indeed, may carry messages from transformed to healthy cells or to other cells in the tumor
or they may signal in an autocrine manner back to the producing tumor cell, thus allowing relevant
changes in recipient cells behavior and microenvironment alterations. Notably, exosomes may deliver
signals able to induce an Epithelial-to-Mesenchymal Transition (EMT), a transdifferentiation process
that underlines tumor dissemination.
In this review, we focus our interest on the role of exosomes during the EMT process in tumor
progression. Starting with an overview on the molecular composition of these vesicles, with a focus on
their emerging heterogeneity, we highlight current knowledge on the exosome-mediated intercellular
communication in tumor niche establishment, migration, invasion, and metastasis processes.
This body of evidence suggests the relevance of taking into account exosome-mediated signaling
and its multifaceted aspects to develop innovative anti-tumoral therapeutic approaches.
2. Exosome Heterogeneity and Cargo Composition
Exosomes are generally characterized by markers such as tetraspanins (e.g., CD63 [10]) and heat
shock proteins (HSP70 and HSP90 [11]) while their biogenesis involves the endosomal sorting complex
required for transport (ESCRT; [12]), Rab proteins [13], syndecan-syntenin-Alix [14], and others.
Despite that, the improvement in the technologies adopted for exosomes isolation and characterization
highlighted that, even if originating within the MVBs and presenting common markers, exosomes may
show physical and chemical differences. Therefore, for a better comprehension of the variety and the
apparent discrepancy of current literature reports, we should consider that exosomes may exhibit per
se heterogeneity, both in physiological and in pathological conditions.
With respect to exosome features, Kowal and collaborators [15] demonstrated by a quantitative
proteomic analysis, that high-speed ultracentrifugation, considered the gold-standard purification
method for exosomes, allows the isolation of four different populations, among which, only
two are associated with the endosomal pathway, and can be further separated for the different
expression/enrichment in tetraspanin Cluster of Differentiation (CD) 63, CD81, and/or CD9.
Interestingly, Willms et al. [16] demonstrated that several cell types release two major subpopulations
of exosomes with distinct molecular compositions and biological properties. At least two different
types of exosomes have been recovered from saliva, differing in size and content in term of proteins
and RNAs [17,18]. Furthermore, the Lotvall group proved that human mast cells release two distinct
exosome families that, separated by floatation on a density gradient, present “substantial” differences
in RNA species content as demonstrated by microarray and Next Generation Sequencing (NGS).
Interestingly, while RNA from Low Density exosome correlated with cellular mRNA, High Density
exosomes were enriched in non-coding RNA (ncRNA). Moreover, differences in RNA signatures
and protein patterns led the authors to hypothesize about possible different exosome biogenesis
pathways [19].
Exosomes with different protein composition and surface markers have been identified after
flotation onto sucrose gradient by Bobrie et al. [20]. These authors reported that high-speed
ultracentrifugation co-purified vesicles bearing the endosomal tetraspanin CD63 together with smaller
vesicles which exposed the CD9 tetraspanin and the peripheral membrane-associated protein Mfge8.
Most interestingly, the discovery that Rab27a, a small GTPase known to be involved in exosome
secretion, is required for the release of the only CD63 positive exosomes, enforcing the hypothesis that
heterogeneity comes from different molecular mechanisms of formation and secretion of exosomes.
With respect to cargo molecules, exosomes embed several macromolecules e.g., lipids, metabolites,
nucleic acids and proteins (the complete lists of exosome embedded macromolecules can be found
on ExoCarta [21] or Vesiclepedia [22]. Cargo molecules depend on the cell of origin, the change in
response to physiological and pathological conditions [23] and maintain their biological function
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when transferred to the receiving cells, impacting their fate [24]. Nucleic acid analysis revealed,
inside exosomes, an abundance of RNA families that, protected from RNases by lipoprotein envelop,
maintain their functions. Notably, specific subsets of miRNAs appear to preferentially localize to
exosomes [25–27] and, as demonstrated by Pegtel at al. [28], exosome-mediated miRNAs delivery
directly modulates specific targets once in the cytoplasm of receiving cells. Even if numerically less
abundant than small RNAs, long non-coding RNAs (lncRNAs) have been found in exosomes released
by different cell types, specifically by tumor cells, thus representing new specific tumor markers [29–31].
However, further studies are required to fully understand the effects induced by non-coding RNAs in
target cells, specifically concerning lncRNAs, whose pleiotropic roles make them protagonists in the
control of gene expression from epigenetics to miRNAs inhibition. Concerning this, two interesting
manuscripts from the Lorico group [32,33] demonstrated that internalized exosomes, or part of these,
can directly reach the nucleus of receiving cells. These data initiate interest on all of the compounds
that, transported by the exosomes, have a nuclear biological activity (e.g., transcription factors, histone
modification enzymes, and lncRNAs).
Deeper investigations are required also to characterize the loading of specific macromolecules.
The study of miRNA-motifs mediated loading are so far limited to a few reports that identified
specific RNA-binding-proteins and some miRNA consensus sequences mediating the process [34–36].
While the mechanisms of selective loading of RNAs, as well as proteins, in exosomes are still poorly
understood, it is conceivable that pH [37] and hypoxia [38] may affect both the entity of the release
and the sorting of a specific content. The lack of standardized well-characterized methods to isolate,
purify, and quantify the exosomes further limits the study of their content as cell signature.
The high variability of exosome-induced effects is also determined by the type of interactions
occurring between exosomes and target cells that, as recently reviewed in [39], are governed by
numerous factors. Depending on their origin, exosomes have been found to interact preferentially
with specific cell types, and this interaction seems to be strongly conditioned by the integrins exposed
on the exosome surface [40]. It is conceivable that an extensive proteomic analysis of adhesion proteins,
such as extracellular matrix proteins (e.g., fibronectin and laminin) and tetraspanins might help to
predict exosome-cell interactions but we lack efficient protocols for the isolation of outer membrane
proteins only.
Once in touch with target cells, the strategy used to transform these are multiple. First, exosomes
may activate receiving cells from the outside, through a ligand/receptor interaction and subsequent
activation of downstream pathways.
Paradigmatic is the immune tolerance induced by several cancer cells through exosomes, which
express death signals as the PD-L1 (programmed death-ligand 1) or Fas Ligand, and systemically
induce apoptosis in receiving T cells and Natural Killer (NK) cells [41,42]. Ligand /receptor
interaction have a role also in exosome migration around the body as recently demonstrated for CCR7
(CC-chemokine receptor 7) that, exposed on the Dendritic Cell exosomes, contributes to both their
migration on spleen and the induction of inflammation [43]. Exosomes expressing the amphiregulin
(AREG), isolated from several tumor cells, have been found able to activate the Epidermal Growth
Factor Receptor (EGFR) in receiving cells thus affecting the bone marrow microenvironment [44] or
promoting bone metastases [45]. Finally, several groups demonstrated a regulation of the Transforming
Growth Factor (TGF)β pathway mediated by membrane-bound molecules [46,47] or (GPI)-anchored
cell surface glycoprotein [48].
In most cases, the interaction with cellular receptors drives exosome internalization. Receptors or
proteins located on the EV surface participate in fusion, endocytosis or phagocytosis with subsequent
release of the exosome content in the receiving cells.
3. EMT Associated with Tumor Progression: The Role of Exosomes
EMT is a physiological or pathological transdifferentiation process in which epithelial cells lose
their cell-cell contacts and apicobasal polarity and acquire mesenchymal properties, coupled to the
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ability to migrate and to invade the surrounding tissues. EMT is crucial in organogenesis, development,
wound healing and regeneration but it is aberrantly activated in tumor progression and metastasis (for
review, [49]). EMT, indeed, allows in situ differentiated cells to acquire the ability to migrate out of
the primary tumor, invading basement membrane and entering the vasculature. Transitional tumor
cells exit from circulation and migrate into the tissue parenchyma in potentially secondary tumor sites.
In this process of colonization of target tissues by metastatic cells (as well as during morphogenesis),
the shift toward a mesenchymal state is often reversed by an inverse Mesenchymal-to-Epithelial
Transition (MET). The MET occurs in different microenvironments and it is necessary to support the
reacquisition of epithelial features to seed metastasis [50,51].
EMT/MET plasticity implies a profound reprogramming of gene expression mainly orchestrated
by specific “master” transcription factors, known as EMT-inducing transcription factors (EMT-TFs;
i.e., ZEB1; SIP1/ZEB2; Twist1; Twist2; E12/E47; Tbx3; the Snail family members Snail2 (Slug), Snail3
(Smuc) and, in particular, Snail1 (Snail) [52–56]. The EMT-TFs primarily act as repressors of the
epithelial genes and may guide the recruitment of the epigenetic machinery to the chromatin context,
thus allowing the proper regulation of gene expression [57,58].
Rather than a simple shift between two alternative states (i.e., the mesenchymal and the epithelial
phenotype), the current view is that the EMT/MET implies multiple and dynamic transdifferentiation
states. This greater flexibility may result in a “partial EMT” or in the co-presence of epithelial
and mesenchymal traits, as in the hybrid “metastable” features identified in several tumors [59–61]
and attributed to a stem phenotype [62–65]. The complexity of the EMT/MET phenotypes reflects
the complexity of the regulatory circuitries that, beyond the transcriptional control, also involve
several ncRNAs, including miRNAs (e.g., miR-200 family or miR-34) [66–68] or lncRNAs (e.g.,
HOTAIR) [57]. Notably, transitional tumor cells need to be continuously reprogrammed to adapt to
different microenvironments and to ensure tumor growth and metastasis [69–71].
Exosome composition profoundly differs between untransformed and transformed cells [72–74]
and increasing evidence suggests that tumor-derived exosomes (TDEs), as well as exosomes from
tumor associated cells in the microenvironment (TME), exert a key role in the regulation of tumor
growth and survival as well as tumor invasion, angiogenesis, and metastasis.
Notably, TDEs may carry pro-EMT cargoes that include EMT inducer molecules, e.g., TGF-β,
Hypoxia-inducible factor (HIF)1α, β-catenin or miRNAs, such as miR-23a. All this content is able to
(i) confer mesenchymal properties to epithelial cells, (ii) promote the initiation phase of the epithelial
tumor metastasis (when in situ tumor cells migrate out of the primary tumor, invading basement
membrane and entering the vasculature) and (iii) guarantee tumor-microenvironment cross-talk [75–80]
(Figure 1A,B).
It is conceivable that a fine tuning of the EMT plasticity may result in the capacity by the cell to
export specific bioactive molecules and, vice versa, the exosome-mediated signaling may impact on
the EMT/MET dynamics. Coherently, exosomes from transitional cells exert a role in the regulation of
tumor niche, migration, invasion, and metastasis.
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by stimulating Cancer Stem Cells maintenance and EMT [83]. Interestingly, exosomes released by 
tumor cells may activate resident fibroblasts inducing CAFs [81,84]. In bladder cancer, Ringuette 
et al. showed that CAF activation is mainly due to the induction of TGFβ/Small Mothers Against 
Decapentaplegic (SMAD) pathway resulting from the transport of TGFβ by TDEs [84]. 
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Figure 1. The role of exosomes in Epithelial-to-Mesenchymal Transition (EMT) and tumor progression
is depicted. (A) Exosomes originate from the multivesicular bodies that release them by fusing with
the cellular membrane. (B) Exosome cargo content of DNA, RNA (including ncRNA) and proteins
specifically mediates cell–cell communication in EMT and in the associated tumor progression to
promote different outcomes.
3.1. Exosomes in Tumor Niche
In primary tumor, exosomes contribute to the definition of tumor niche by promoting tumor
growth (despite nutrient deprivation and stress condition), immune suppression and drug resistance,
and enhancing vasculogenesis.
Cell growth can be stimulated by cytokines that, loaded in TDEs, are then transported to closer
tumor cells; Raimondo et al. demonstrated that exosomes released by chronic myeloid leukemia cells
promoted tumor cell growth and inhibited apoptosis by activating TGFβ receptor [46]. Moreover,
TDEs can induce proliferation of adjacent cells by non-coding RNA-mediated signaling e.g., the
miR-27 in gastric cancer exosomes [81] and the lncRNA c-Myc-Upregulated (MYU) in prostate cancer
exosomes [82]. Meanwhile, paracrine stimulation of tumor cell proliferation is induced by cancer
associate fibroblasts (CAFs). These cells are pivotal players in the tumor microenvironment by
stimulating Cancer Stem Cells maintenance and EMT [83]. Interestingly, exosomes released by tumor
cells may activate resident fibroblasts inducing CAFs [81,84]. In bladder cancer, Ringuette et al. showed
that CAF activation is mainly due to the induction of TGFβ/Small Mothers Against Decapentaplegic
(SMAD) pathway resulting from the transport of TGFβ by TDEs [84]. Furthermore, in gastric cancer an
important contribute to fibroblasts activation is due to the exosome mediated transport of miR-27a [81].
The contribution of CAF released exosomes to tumor growth is supported by studies investigating
CAF proteome and transcriptome that identified a huge number of molecules with pro tumorigenic
activity [85,86]. Interestingly, Zhang and colleagues underlined the possibility that exosomes may
carry both pro- and anti-tumor factors. These authors, in fact, by comparing miRNA sequencing
of exosomes derived from CAFs and exosomes secreted by fibroblasts from HCC (Hepatocellular
Carcinoma) patients, demonstrated that CAF-derived exosomes stimulate cell proliferation lacking
protective elements such as the miR-320a that, on the contrary, is transported by NF-exo and is able to
inhibit HCC growth through MAPK targeting [87].
TDEs may also contribute to acidification of the tumor microenvironment by modulating stromal cell
metabolism. Recently, it was demonstrated that human melanoma-derived exosomes, once internalized
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by dermal fibroblasts, promote aerobic glycolysis and downregulate oxidative phosphorylation [88].
Meanwhile, the Nagrath group elegantly demonstrated that exosomes from CAFs downregulate
mitochondrial activity and increase glycolysis. Furthermore, intra-exosome metabolomic analyses
showed that exosomes contain metabolites, amino acids, and lipids, “which can fuel the metabolic
activity of the recipient cells” [89].
Finally, as mentioned above, exosomes indirectly support tumor growth by favoring immune
escape in different ways; they inactivate T cells or induce their apoptosis by cell surface interaction or
after internalization [90–92]. With respect to immunomodulatory properties, TDEs exposing CD39
and CD37 on their surface can mediate T-cell suppression by extracellular adenosine production [93].
Meanwhile it was shown that the internalization by Kupffer cells of pancreatic ductal adenocarcinoma
TDEs induced fibronectin production, thus promoting the gathering of bone marrow-derived
macrophages and neutrophils and leading to liver pre-metastatic niche formation [94].
A key component of tumor microenvironment is the vascular network that supports tumor
growth; several extracellular mechanisms take part in endothelial cell stimulation, among these TDEs
contribute to modulating both angiogenesis and vascular permeability [95].
It is of note that the ability to promote angiogenesis has been mainly attributed to exosomes
isolated from tumor initiating cells (TICs). In renal cell carcinoma and hepatocellular carcinoma for
example, only CD105+ and CD90+ cells respectively, release exosomes able to stimulate production
and release of the Vascular Endothelial Growth Factor (VEGF); TIC derived exosomes, once engulfed
in endothelial cells, activate the VEGF autocrine loop through the delivery of different ncRNAs [31,96].
Recently, Sun et al. demonstrated pro-angiogenetic activity also in exosomes from Glioma stem
cells, that stimulate endothelial cell motility by activating a miR-21/VEGF/Vascular Endothelial
Growth Factor Receptor (VEGFR) 2 signal pathway [97]. In addition, exosomes can directly stimulate
endothelial cell VEGF receptor through the delivery of 90-kDa VEGF (VEGF90k), which was found to
interact with Hsp90 in extracellular vesicles [98].
Several observations correlate hypoxia, exosomes, and neo angiogenesis stimulation. Low oxygen
partial pressure, a common characteristic of all types of cancer, induces activation and nuclear
translocation of the transcription factor HIF1 that, inside the nucleus, interacts with several co-factors
to induce the up regulation of a huge number of genes whose coordinated expression drives tumor
cells to a most aggressive phenotype [99]. Among the HIF target is the VEGF. Evidence collected in
past years demonstrated that hypoxia stimulates production and release of exosomes [100] that, in turn
participate in promotion of tumor neo-angiogenesis as described by ref. [101] and enclosed references.
Although VEGF signaling is the best-validated pathway in angiogenesis, the refractoriness to
anti-VEGF therapies in several cancers highlighted the involvement of VEGF-independent strategies in
promoting tumor angiogenesis [102]. An interesting study performed by Tang et al. [103] demonstrated
that exosomes, released by ovarian cancer cells, participate in cleavage and delivery of soluble
E-cadherin that once delivered on endothelial cell surface, interacts with VE-cadherin and induces
activation of β-catenin and Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB)
signaling, resulting in endothelial cell migration, and tube formation in vitro and in vivo.
3.2. Exosomes in Migration, Invasion, and Metastasis
A body of evidence points to the role of exosome-triggered EMT in the inception of high metastatic
potential that correlates with high motility and increased invasiveness. Exosomes from cancer cells
were found to be able to activate intracellular pathways by transporting specific proteins such as
phosphorylated tyrosine kinases receptor (RTKs) [104]. Exosomes from muscle-invasive bladder cancer
induced a decrease in E-cadherin expression and enhanced migration and invasion of uroepithelial
cells [79]. Similarly, exosomes from highly metastatic lung cancer cells induced an EMT associated with
migration, invasion, and proliferation in recipient human bronchial epithelial cells [105]. Furthermore,
exosomes secreted by highly metastatic MHCC97H hepatocarcinoma (HCC) cells conferred the ability
to migrate and give invasiveness properties to low metastatic HCC cells by inducing EMT via
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MAPK/Extracellular signal-Regulated Kinase (ERK) signaling pathway activation [106]. Finally,
human breast and colorectal cancer cells released full-length, signaling-competent EGFR ligands,
i.e., amphiregulin, able to increase the invasiveness of recipient cancer cells [107].
Harris et al. investigated the role of exosomes released from different breast cancer cells, modeling
different stages of metastasis. They showed that tumor cells of increasing metastatic potential are
able to secrete exosomes with protein signatures different in identity and abundance; these exosomes
increased cell migration proportionally, with exosomes from high-metastatic potential cells able to
induce the greatest degree of cell movement [108]. Interestingly, xenograft tumor cell motility studies
in the chorioallantoic membrane (CAM) of chick embryos revealed a key role of exosome secretion
for the directional migration of fibrosarcoma cells. These vesicles, indeed, carry extracellular matrix
(ECM) molecules promoting adhesion assembly [109].
Furthermore, Schillaci et al. [110] recently demonstrated that exosomes released by metastatic
colon cancer cell lines affected tumor behavior promoting a more aggressive phenotype. They found
that metastatic amoeboid cells (SW620) release exosomes that are enriched in Thrombin, activating
RhoA/Rho-associated protein kinase (ROCK) pathway in receiving cells. This activation induces
migration and invasion in primary tumor cells while, in endothelial cells, causes VE-cadherin
delocalization and junction disruption.
Concerning exosomal lncRNAs, a role for BCAR4 (breast cancer anti-estrogen resistance 4) has
been suggested in colorectal cancer development [111] while HOTAIR (Hox antisense intergenic
RNA) was found overexpressed in bladder cancer patients and correlated with the invasiveness
of the tumor [30]. Notably, HOTAIR has a key functional role in promoting EMT in different cell
types [57,112,113].
With respect to TMEs, Luga et al. demonstrated that CD81-positive CAF-released exosomes
induced in breast cancer cells the release of Wnt11 that, in an autocrine manner, promoted the
activation of Planar Cell Polarity (PCP) [114]. Meanwhile, Condorelli’s group attributed the induction
of EMT in breast cancer to three different miRNAs (miRs-21, -378e, and -143), delivered by CAF-derived
exosomes [115]. These observations enforced the idea that cellular transformation, induced by exosome
uptake, must be mediated by multiple biological compounds that converge on the same molecular
pathways. Li and collaborators demonstrated that ovarian CAF-derived exosomes were enriched
in TGFβ1 that may induce an EMT and an aggressive phenotype in ovarian cancer cells lines [116].
More recently, Zhao and colleagues demonstrated that human umbilical cord mesenchymal stem
cells-derived conditioned medium was able to induce migration and invasion capability in A549 lung
cancer cells by activating TGFβ-related pathways [117].
The ability to migrate and invade surrounding tissues can be enhanced by hypoxia-induced
exosomes by shuttling different molecules. Firstly, exosomes released in hypoxia may contain
hypoxia-inducible factors (HIFs), able to trigger EMT in recipient cells [78]. Coherently, Ramteke and
colleagues showed that hypoxia-induced exosomes increased the invasiveness of prostate cancer cells
by promoting the loss of E-cadherin [118]. Furthermore, exosome-mediated mechanisms to promote
migration and invasiveness by tumor cells in hypoxia may involve lncRNAs, such as UCA1 in bladder
cancer cells [119] or the lncRNA-regulator of reprogramming (RoR) in HCC [120], as well as specific
miRNAs, e.g., miR-21 in oral squamous cell carcinoma [94] or miR-23a in lung cancer [121].
Interestingly, Zhou and colleagues reported that exosomes secreted by cervical squamous cell
carcinoma (CSCC) cells may shuttle miR-221-3p, targeting vasohibin1 (VASH1), to human lymphatic
endothelial cells (HLECs). This promotes migration in vitro as well as lymphangiogenesis and lymph
node metastasis in vivo [122].
The role of TDEs is not limited to the primary tumor site and their ability to cross long distances
within the body makes exosomes a suitable vehicle to trace the way of tumor metastases. TDEs
promote the organotropism of metastatic tumors and contribute to pre-metastatic niche formation by
showing “avidity” for specific recipient cells [11,40,94]. Notably, Hoshino and colleagues showed that
the exosomal integrins guide the exosomes to specific secondary sites. Furthermore, exosomes from
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lung-, liver- and brain-tropic tumor cells preferentially fuse with lung fibroblasts and epithelial cells,
liver Kupffer cells, and brain endothelial cells [40].
4. Conclusions and Perspectives
EMT exerts a key role in tumor progression and exosomes, released by transitional cells, transport
specific signaling molecules to promote invasion, migration, metastasis, and microenvironment
changes, able to sustain tumor growth and dissemination. In fact, the horizontally transferred TDE
specific content promotes the acquisition by tumor cells of mesenchymal markers and increases
cell motility, associated with a more aggressive phenotype. Furthermore, exosome cargo impacts
on tumor niche establishment and regulates the tropism of metastasis (Tables 1 and 2). Therefore,
the identification of molecules (mRNA, ncRNAs, proteins) specifically enriched in exosomes from
different tumor stages may represent an efficient real-time staging of tumor evolution or response to
therapy, also in patients differing in gender or age. Notably, EVs may be isolated from body fluids, and
several RNA and protein molecules have already been identified as potential diagnostic and prognostic
biomarkers of different tumor types or different stages of the same tumor. Interestingly, the study of
the secretome of HCC cells overexpressing the master transcriptional factor Slug, and exhibiting a
partial EMT phenotype, showed the enrichment in exosomes of Fibronectin 1 (FN1), collagen type II
alpha 1 (COL2A1), and fibrinogen gamma chain (FGG); therefore, these proteins may represent useful
and non-invasive biomarkers associated with partial transitional cells [123]. Notably, a partial EMT
may characterize circulating tumor cells (CTCs) that pose a metastatic risk for patients [124].
Table 1. Summary of recent evidence on exosome signaling molecules and their effects on tumor progression.
Exosome-Mediated
Effect Producing Cell Specific TDE Content and Mechanism of Action Reference
Tumor cell proliferation
Prostate cancer cells
lncRNAc-Myc Upregulated (MYU)-mediated
upregulation of c-Myc by competitively binding
miR-184
[82]
Hypoxic bladder cancer cells lncRNA-UCA (unknown mechanism) [119]
Hypoxic hepatocellular
carcinoma cells
lncRoR-induced hypoxic responses (by
downregulation of miR-145 and upregulation of
Hypoxia-inducible factor 1 (HIF1)
[120]
CAF from Human Oral Tongue
Squamous Cell Carcinoma
MFAP5 (Microfibril Associated Protein 5)-induced
activation of mitogen-activated protein kinase
(MAPK) and AKT
[85]
CAF from Hepatocellular
carcinoma MAPK activation by negative regulation of miR-320a [87]
CAF from pancreatic ductal
adenocarcinomas Snail and microRNA-146a upregulation [125]
EMT and metastasis of
tumor cells
Bladder cancer cells Colon cancer
cell lines
RhoA/ROCK (Rho-associated protein kinase)
signaling pathway activation and acquisition of
migratory capacity
[79,110]
Epstein-Barr-Virus EBV infected
Nasopharyngeal carcinoma (NPC) HIF1 upregulation [78]
metastatic melanoma cells MET induced pro-vasculogenic andmetastatic effects [11]
Hypoxic cancer cells Activation of Epithelial-to-Mesenchymal Transition(EMT) genes in receiving cells
[101] and
enclosed
references
Lung cancer cells vimentin [105]
Hepatocellular carcinoma cells MAPK/ERK (Extracellular signal-Regulated Kinase)signalling activation (unknown mechanism) [106]
High aggressive breast cancer proteins involved in metastasis and invasion [108]
Prostate cancer cells metalloproteinases induction and targeting ofadherens junction proteins [118]
Hypoxic bladder cancer lncRNA-UCA1 (Urothelial Cancer Associated 1)(mechanism of action unspecified) [119]
Metastatic breast cancer miR-10b targeting HOXD10 (HomeoboxD10) [126]
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Table 1. Cont.
Exosome-Mediated
Effect Producing Cell Specific TDE Content and Mechanism of Action Reference
CAF from Human Oral Tongue
Squamous Cell Carcinoma MFAP5 activation of MAPK and AKT [85]
CAF from Hepatocellular
carcinoma MAPK activation [87]
CAF from breast cancer EMT activation by miRs -21, miR-378 and miR-143 [115]
CAF from ovarian cancer TGF (Transforming Growth Factor) β1-induced EMT [116]
Mesenchymal stem cells
TGFβ1 activation of Smad2/3, Akt/GSK (Glycogen
synthase kinase)-3β/β-catenin, NF-κB (Nuclear
Factor kappa-light-chain-enhancer of activated B
cells), ERK (Extracellular signal-Regulated Kinase),
JNK (c-Jun N-terminal kinase and p38 MAPK
(mitogen-activated protein kinase)
[117]
Table 2. Summary of recent evidence on exosome signaling molecules and their effects in the
tumor microenvironment.
Tumor Microenvironment
Modification Producing Cell Specific Content and Mechanism of Action Reference
CAF activation
Gastric cancer cells miR-27a-mediated downregulation of CSRP2 (cysteineand glycine rich protein 2) [81]
Bladder cancer cells TGFβ–induced SMAD (small mothers againstdecapentaplegic) activation [84]
Pancreatic ductal
adenocarcinomas
Stellate cells activation and induction of a
pro-inflammatory milieu. (unknown mechanism) [94]
Prostate cancer cells
Induction of TGF-β2, TNF1α (Tumor necrosis factor1 α),
IL6 (Interleukin 6), TSG101 (Tumor susceptibility gene
101), Akt, ILK1 (Integrin-linked kinase1) and β-catenin.
[118]
Angiogenesis and vascular
permeability
Cancer Stem Cells from
Hepatocellular Carcinoma
lncRNA H19-mediated VEGF (Vascular endothelial
growth factor) induction [31]
Metastatic breast cancer miR-105 targeting of ZO-1 [95]
Glioma stem cells miR21-mediated induction of VEGF pathway. [97]
Hypoxic cancer cells Upregulation of miR-135-b, miR-23a, miR-210, miR-494and Wnt pathway activation.
[101] and
enclosed
references
Ovarian cancer
E-cadherin-mediated activation of β-catenin and NFκB
(Nuclear Factor kappa-light-chain-enhancer of activated B
cells) signaling
[103]
Cervical squamous cell carcinoma miR-221-3p-mediated activation of the ERK (Extracellularsignal-Regulated Kinase)/AKT pathway [122]
Immunomodulation
Head and neck squamous cell
carcinoma
Receptor–ligand interactions regulating gene expression in
T cells [90]
Melanoma cells miR-690 induction of mitochondrial apoptotic pathway inCD4+ T cells [91]
Several cancer cells miRNAs regulation
[92] and
enclosed
references
Lung adenocarcinoma,
hepatocellular carcinoma, breast
carcinoma
Monocyte recruitment and Generation of Tumor
Associated Macrofages [104]
Hypoxic lung cancer
miR-103a-mediated targeting of PTEN (Phosphatase and
tensin homolog) and activation of Tumor Associated
Macrofages
[120]
Chemoresistence and Cancer
Stem Cell stimulation
CAF from colon rectal cancer Wnt3a induction of WNT signalling activation in CSC(Cancer Stem Cells) [127]
CAF from breast cancer miR-21, miR-378e and mir-143-mediated Cancer StemCells maintenance [113]
Renal cell carcinoma lncRNA ARSR-mediated chemoresistance viacompetitively binding of miR-34/miR-449. [128]
Metabolism modulation
Melanoma cells miR-155 and miR-210-mediated promotion of glycolysisand inhibition of oxidative phosphorylation. [88]
CAF from prostate cancer and
from pancreatic cancer
Metabolites inhibiting mitochondrial oxidative
phosphorylation and increasing glycolysis. [89]
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All further efforts in the study of biomarkers would have a great impact particularly on early
diagnosis, considering that the development of non-invasive diagnostic tools currently represents
a major challenge. Moreover, an optimization of exosome isolation protocols is required to better
disclose the functional role of specific exosome cargo molecules. The isolation of exosomes with high
purity and quality is still difficult and the demonstrated heterogeneity of exosomes further impairs
the isolation efficiency; all these aspects represent a limitation, particularly for the study of low copy
number molecule species, such as lncRNAs.
A deep understanding of mechanisms controlling the loading of specific molecules in exosomes
is also needed. This field of study is to be considered still at infancy even if some mechanisms of
sequence-specific miRNA sorting (by EXO- and hEXO-motifs) and specific heterogeneous nuclear
ribonucleoproteins (hnRNPA2B1 and hnRNPQ) involved in the recognition of these signals, have
been recently identified [34,35]. Interestingly, the sorting of lncRNA ARSR in exosomes by renal
cancer cells also involves hnRNPA2B1 [128]; furthermore, a “zipcode” in the mRNAs may control
their selective loading [129]. All of this evidence suggests common regulative mechanisms, at least
for RNA loading, and opens the way towards possible innovative therapeutic strategies oriented
to the selective modulation of RNA exosomal cargo by engineering signaling sequences. Other
approaches could aim to interfere with, or promote, the in vivo sorting of these vesicles. The use of
specific inhibitors, targeting key regulators of both exosome biogenesis and release, could be a suitable
approach. For example, the release of EVs by primary hepatocytes and Huh7 cells may be reduced by
inactivating mediators of the DR5 signaling pathway or ROCK1 inhibition. Interestingly, the ROCK1
inhibitor fasudil reduced serum levels of EVs in nonalcoholic steatohepatitis (NASH) mice and this
reduction was associated with decreased liver injury, inflammation, and fibrosis [130]. The drug
GW4869 was efficiently used to inhibit exosome biogenesis by interfering with sphingomyelinase
function [125,126]. The release of exosomes was shown to be influenced by calcium and the monensin
drug was found able to affect exosome biogenesis [131]. Further studies are still necessary to investigate
the effective translational application of these protocols.
Remarkably, exosomes show low immunogenicity, high biocompatibility, and high efficacy of
delivery. Considering all these features, they might be engineered to convey molecules of interest and
achieve targeted therapeutic intervention. For a recent example, paclitaxel-loaded exosomes, modified
to improve circulation time, were shown to selectively deliver the drug to target cancer cells and
increase the survival rate of lung cancer patients [132].
Finally, an in-depth understanding of exosome cargo composition and functional role in EMT
associated with tumor progression would pave the way for innovative therapeutic opportunities.
In particular, further studies must be focused on the characterization and potential engineering in vivo
and/or ex vivo of exosomes from EMT cells. The plasticity of transitional cells might, indeed, imply a
fine-tuning regulation of the loading machinery that, in turn, might be mirrored by the great complexity
of exosome cargoes.
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